Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-01-30
1999-11-23
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 9464, 424422, 424423, 435212, 530381, 530384, 530830, A61K 3836, A61K 3516, A61F 1300, C07K 14435
Patent
active
059900792
ABSTRACT:
Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.
REFERENCES:
patent: 4337244 (1982-06-01), Smith
patent: 4382083 (1983-05-01), Thomas
patent: 4604285 (1986-08-01), Faith et al.
patent: 4970300 (1990-11-01), Fulton et al.
patent: 5114851 (1992-05-01), Porter et al.
patent: 5278144 (1994-01-01), Wolf
patent: 5583107 (1996-12-01), Wolf et al.
patent: 5597799 (1997-01-01), Wolf
patent: 5837679 (1998-11-01), Wolf et al.
Bernardi, et al., "Partial Gene Deletion in a Family with Factor X Deficiency" Blood, vol. 73, No. 8, 2123-2127 (1989).
Cassels, et al., "The Interaction of Streptokinase Plasminogen Activator Complex, Tissue-Type Plasminogen Activator, Urokinase and their Acylated Derivatives with Fibrin and Cyanogen Bromide Digest of Fibrinogen" Biochem. J. 247, 395-400 (1987).
Crabbe, et al., "Acylated Plasminogen-Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy" Pharmacotherapy, vol. 10, No. 2, 115-126 (1990).
Davie, "The Blood Coagulation Factors: Their cDNAs, Genes, and Expression" Plasma Coagulation Factors, 242-267.
DiScipio, et al., "Activation of Human Factor X (Stuart Factor) by a Protease from Russell's Viper Venom" Biochemistry, vol. 6, No. 24, 5253-5260 (1977).
Dunwiddie, et al., "Antistasin, a Leech-Derived Inhibitor of Factor Xa" The Journal of Biological Chemistry, vol. 264, No. 26, 16694-16699 (1989).
Etingin, et al., "Viral Activation of the Coagulation Cascade: Molecular Interactions at the Surface of Infected Endothelial Cells" Cell, vol. 61, 657-662 (1990).
Fair, et al., "Isolation and Characterization of the Factor X Friuli Variant" Blood, vol. 73, No. 8, 2108-2116 (1989).
Fears, "Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept" Seminars in Thrombosis and Hemostasis-Vol. 15, No. 2, 129-139 (1989).
Fears, et al., "The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma" Drugs 33 (Suppl. 3, 57-63 (1987).
Furie, et al., "The Molecular Basis of Blood Coagulation" Cell, vol. 53, 505-518 (1988).
Girard, et al., "Functional Significance of the Kunitz-Type Inhibitory Domains of Lipoprotein-Associated Coagulation Inhibitor" Nature, vol. 338, 518-520 (1989).
Girard, et al., "Inhibition of Factor VIIa-Tissue Factor Coagulation Activity by a Hybrid Protein" Science, vol. 248, 1421-1424 (1990).
Hassan, et al., "Multiple Polymorphic Sites in Factor X Locus" Blood, vol. 71, No. 5, 1353-1356 (1988).
Hoover, et al., "The Adhesive Interaction between Polymorphonuclear Leukocytes and Endothelial Cells in Vitro" Cell, vol. 14, 423-428 (1978).
Husten, et al., "The Active Site of Blood Coagulation Factor Xa" The Journal of Biological Chemistry, vol. 262, No. 27, 12953-12961 (1987).
Krishnaswamy, et al., "Prothrombinase Complex Assembly" The Journal of Biological Chemistry, vol. 263, No. 8, 3823-3834 (1988).
Levine, "Clinical Manifestations and Therapy of Hemophilias A and B" Plasma Coagulation Factors, 97-111.
Nesheim, et al., "The Contribution of Bovine Factor V and Factor Va to the Activity of Prothrombinase" The Journal of Biological Chemistry, vol. 254, No. 21, 10952-10962 (1979).
Nesheim, et al., "Cofactor Dependence of Factor Xa Incorporation into the Prothrombinase Complex" The Journal of Biological Chemistry, vol. 256, No. 13, 6537-6540 (1981).
Reddy, et al., "Molecular Characterization of Human Factor X.sub.San Antonio " Blood, vol. 74, No. 5, 1486-1490 (1989).
Skogen, et al., "Comparison of Coagulation Factor Xa and Des-(1-44) Factor Xa in the Assembly of Prothrombinase" The Journal of Biological Chemistry, vol. 256, No. 4, 2306-2310 (1984).
Steinberg, et al., "Activation of Factor X" Plasma Coagulation Factors, 112-119.
Sturzebecher,et al., "Stable Acyl-Derivatives of Tissue-Type Plasminogen Activator" Thrombosis Research 47, 699-703 (1987).
Watzke, et al., Molecular Defect (Gla.sup.+14 .fwdarw.Lys) and its Functional Consequences in a Hereditary Factor X Deficiency (Factor X "Vorarlberg") The Journal of Biological Chemistry, vol. 285, No. 20, 11982-11989 (1990).
Waxman, et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" Science, vol. 248, 593-596 (1990).
Neuenschwander et al Anal Biochem. 184 347-352 1990.
Nucir et al Adv. Drug Del. Rev 6 133-151 1991.
Fuy et al PNAS 82 3591-3595 1985.
Parrish, "New Concepts In Therapeutic Photomedicine: Photochemistry, Optical Targeting & The Therapeutic Window" J Invest Dermatol. 77(1) 45-50, Jul. 1981.
Sinha Uma
Wolf David L.
COR Therapeutics Inc.
Degen Nancy
LandOfFree
Agents affecting thrombosis and hemostasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents affecting thrombosis and hemostasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents affecting thrombosis and hemostasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1221928